Alternatively, ERBB2 may exert its predisposition to MPN acquisition by pathways that are not intrinsic or specific to hematopoietic cell signaling or development, such as genomic instability, inflammation, telomere biology, or other pathways implicated in cancer susceptibility [17,45,46,47]. This evidence concerns the gene ERBB2 and cancer.